M E Grossman

Columbia University, New York City, New York, United States

Are you M E Grossman?

Claim your profile

Publications (156)799.64 Total impact

  • Leukemia & lymphoma. 10/2014;
  • [Show abstract] [Hide abstract]
    ABSTRACT: Acquired cutis laxa is a rare cutaneous manifestation of hematologic malignancy. We report a case of γ heavy chain deposition disease (HCDD) associated with acquired cutis laxa, renal involvement, and hypocomplementemia and propose a mechanism of elastic fiber degradation in the skin of this patient with HCDD.
    JAMA dermatology. 08/2014;
  • Source
    [Show abstract] [Hide abstract]
    ABSTRACT: Long-standing burns, fissures, and ulcers that undergo malignant transformation into a variety of malignancies, including squamous cell carcinoma, is commonly referred to as a Marjolin's ulcer. It is well recognized that squamous cell carcinomas of the lung and esophagus can cause humoral hypercalcemia of malignancy secondary to paraneoplastic secretion of parathyroid hormone-related peptide. However, it is extremely rare for a squamous cell carcinoma developing in a sacral decubitus ulcer to cause humoral hypercalcemia of malignancy. We describe the first case of a patient found to have elevated serum levels of parathyroid hormone related peptide related to his Marjolin's ulcer. A 45-year-old African American man with T6 paraplegia and a sacral decubitus ulcer present for 20 years was admitted for hypercalcemia of unclear etiology. He was subsequently found to have elevated parathyroid hormone related peptide and an excisional biopsy from the ulcer showed invasive squamous cell carcinoma suggestive of humoral hypercalcemia of malignancy. The patient ultimately succumbed to sepsis while receiving chemotherapy for his metastatic squamous cell carcinoma. Humoral hypercalcemia of malignancy is a rare and likely underrecognized complication that can occur in a Marjolin's ulcer.
    Case reports in medicine. 01/2014; 2014:715809.
  • [Show abstract] [Hide abstract]
    ABSTRACT: Generalized verrucosis is a characteristic of several genetic and immunodeficiency disorders including epidermodysplasia verruciformis, WHIM syndrome, WILD syndrome, severe combined immune deficiency, and HIV, among others. In recent years, it has been consistently recognized in patients with GATA2 deficiency, a novel immunodeficiency syndrome characterized by monocytopenia, B-cell and natural killer cell lymphopenia, a tendency to develop myeloid leukemias and disseminated mycobacterial, human papillomavirus, and opportunistic fungal infections. Mutations in GATA2 cause haploinsufficiency and track in families as an autosomal dominant immunodeficiency. GATA2 is a transcription factor involved in early hematopoietic differentiation as well as lymphatic and vascular development. We describe a case of generalized verrucosis with HPV type 57 presenting in a young man with GATA2 deficiency. GATA2 deficiency is a novel dominant immunodeficiency that is often recognized later in life and should be considered in the differential diagnosis of patients with generalized verrucosis. This article is protected by copyright. All rights reserved.
    British Journal of Dermatology 12/2013; · 3.76 Impact Factor
  • M M Levender, D N Silvers, M E Grossman
    [Show abstract] [Hide abstract]
    ABSTRACT: IgA gammopathy and multiple myeloma have been associated with multiple neutrophilic dermatoses including subcorneal pustular dermatosis(1-4) erythema elevatum diutinum(5) , urticarial vasculitis,(6) Sweet's syndrome(7) and pyoderma gangrenosum.(8) We report an unusual urticaria-like neutrophilic dermatosis as the presenting sign of IgA myeloma. An 84 year old woman with cardiomyopathy, atrial fibrillation, rectal cancer in remission, and hypertension was admitted for syncope. She reported bone pain and an intermittent rash over the preceding months. Laboratory studies were notable for normocytic anemia, normal white blood cell count negative serologies for HTLV-1, RPR, hepatitis, and HIV, widespread osteolytic lesions on skeletal survey, elevated serum IgA (1080 mg/dL, normal: 70-350), decreased serum IgG (599 mg/dL, normal: 700-1700) and IgM (<6.5 mg/dL, normal: 50-300) and a monoclonal IgA Kappa on serum protein electrophoresis consistent with plasma cell dyscrasia and confirmed with bone marrow biopsy, demonstrating 15% atypical plasma cells. This article is protected by copyright. All rights reserved.
    British Journal of Dermatology 12/2013; · 3.76 Impact Factor
  • JAMA dermatology (Chicago, Ill.). 07/2013;
  • [Show abstract] [Hide abstract]
    ABSTRACT: Chlorhexidine gluconate-impregnated dressings have become widely adopted as a means to reduce the risk for catheter-associated bloodstream infections. These dressings release antiseptic under occlusion onto the skin surrounding catheter insertion sites. Although chlorhexidine gluconate is a known cause of contact dermatitis, the phenotypic range of this adverse effect of chlorhexidine gluconate–impregnated dressings in critically ill patients has not been described. We report 7 cases of erosive irritant contact dermatitis due to chlorhexidine gluconate-impregnated transparent dressings. Six of these patients were children (age range, 4 months to 2 years); the adult was a critically ill 62-year-old man. Four patients were immunosuppressed after solid organ transplant and all were receiving blood pressure support at the time of this reaction. The insertion sites of femoral catheters were involved in all but 1 case; 3 catheter sites were involved in the adult patient. Results of extensive infectious workups were negative. All lesions resolved with discontinuation of the chlorhexidine gluconate-containing dressings, local wound care, and alternative antimicrobial dressings. Erosive contact dermatitis is an under-recognized complication of chlorhexidine gluconate-impregnated dressings. Health care providers should be aware of this risk, particularly in young children and immunosuppressed and/or critically ill patients, who may be more susceptible to the irritant effects of these dressings. When the dressings are used, patients should be monitored closely for skin breakdown.
    JAMA dermatology (Chicago, Ill.). 02/2013; 149(2):195-9.
  • Mina Y Kingsbery, Marc E Grossman, Huyen Nguyen
    Journal of the American Academy of Dermatology 02/2013; 68(2):e60-1. · 4.91 Impact Factor
  • International journal of dermatology 01/2013; · 1.18 Impact Factor
  • Journal of the American Academy of Dermatology 10/2012; 67(4):e160-2. · 4.91 Impact Factor
  • Cutis; cutaneous medicine for the practitioner 04/2012; 89(4):173-4. · 0.82 Impact Factor
  • Channing R Barnett, Farrah S Bakr, Marc E Grossman
    [Show abstract] [Hide abstract]
    ABSTRACT: Cutaneous angiosarcoma is a rare aggressive malignancy of vascular origin that usually arises in the scalp or face of elderly men. We describe a case of primary cutaneous angiosarcoma with skin metastases and presumed metastases to the lung in a 58-year-old man who presented with persistent bloody pleural effusions, an asymptomatic nontraumatic red patch on the forehead of 2 to 3 months' duration, and a pair of purpuric papules on his left mid back of unknown duration. Cutaneous metastases of angiosarcoma are uncommon. Spontaneous persistent bloody effusions without hemoptysis are distinctly uncommon, and pleural fluid cytology is repeatedly negative in lung or pleural angiosarcoma, making it difficult to diagnose without tissue biopsy.
    Cutis; cutaneous medicine for the practitioner 03/2012; 89(3):129-32. · 0.82 Impact Factor
  • Alexis L Young, Jackleen Marji, Marc E Grossman
    [Show abstract] [Hide abstract]
    ABSTRACT: Cutaneous drug eruptions are a common adverse reaction to medication. Creation of a drug calendar that covers a two-week span prior to the onset of rash is useful to identify the culprit agent. However, the creation of a drug calendar is often labor intensive. We developed an electronic version of a drug calendar that has considerably increased the ease and efficiency of completing a dermatology consultation.
    Journal of drugs in dermatology: JDD 12/2011; 10(12):1430-1. · 1.16 Impact Factor
  • [Show abstract] [Hide abstract]
    ABSTRACT: Esophageal lichen planus (ELP) is a rare manifestation of mucocutaneous lichen planus (LP). We aimed to report our experience and review all cases of ELP reported in the English-language literature. We report our experience with 4 cases and reviewed PubMed for reports of ELP. Cases were evaluated for age of onset, sex, location of LP, relationship of the onset of ELP to extra-ELP, endoscopic findings, whether biopsy was performed, histopathology of esophageal biopsy specimens, medical history (including gastrointestinal history), development of esophageal squamous cell carcinoma, therapies tried, and response to treatment. A total of 72 cases of ELP were studied. In all, 87% of patients were female, with a median age of 61.9 years at time of diagnosis. Dysphagia was present in 81% and odynophagia was present in 24%. Oral LP was present in 89%, anogenital/vulvar LP in 42%, and cutaneous LP in 38%. Fourteen patients developed ELP as the sole or first manifestation of LP. Proximal esophageal lesions were present in 64%, distal in 11%, and both proximal and distal in 26%. Histology was "consistent with" LP in 71%. Four patients developed squamous cell carcinoma in association with ELP. This is a review of our cases and others reported in the literature. ELP is underrecognized and underreported. There is often a significant delay between the onset of symptoms and the diagnosis. Malignant transformation of ELP to squamous cell carcinoma has been reported.
    Journal of the American Academy of Dermatology 07/2011; 65(1):175-83. · 4.91 Impact Factor
  • [Show abstract] [Hide abstract]
    ABSTRACT: Anti-epiligrin cicatricial pemphigoid is an autoimmune blistering disorder that has recently been associated with the development of solid organ malignancy. We describe a patient with recurrent metastatic prostate carcinoma who was diagnosed with this disorder. We provide a hypothesis as to the relationship between the development of this disease and its possible association with cancer pathogenesis.
    European journal of dermatology: EJD 04/2011; 21(3):401-4. · 1.95 Impact Factor
  • [Show abstract] [Hide abstract]
    ABSTRACT: Cutaneous calcification is an acquired disorder whereby insoluble, amorphous calcium salts deposit in the skin. Classically, cutaneous calcification is categorized as metastatic, dystrophic, idiopathic, or iatrogenic. The purpose of this study was to further elucidate the underlying pathogenic mechanism for cutaneous calcification. Three cases of cutaneous calcification, including clinical characteristics and associated histopathology, were reviewed. Previous reports of cutaneous calcification were searched for in the published literature and included. Calcium is distributed within areas of underlying tissue damage (ie, locus minoris resistentiae), and in our cases, occurred specifically at sites of chronic actinic damage and intravenous extravasation tissue injury. A small number of clinical cases and previously published reports were reviewed. We hypothesize that cutaneous calcification may preferentially occur at anatomic sites where tissue integrity has been compromised (ie, locus minoris resistentiae). We suggest one potential mechanism: that cutaneous calcification occurs within dermis that contains damaged elastic fibers. Pseudoxanthoma elasticum may serve as a possible genetic disease model for this process.
    Journal of the American Academy of Dermatology 02/2011; 64(2):296-301. · 4.91 Impact Factor
  • [Show abstract] [Hide abstract]
    ABSTRACT: Henoch-Schönlein purpura (HSP) is an immune complex-mediated systemic small vessel vasculitis that is most commonly described in children but may affect patients of any age. Our patient, a 91-year-old man, presented with anuria caused by IgA-mediated nephropathy; he later developed cutaneous leukocytoclastic vasculitis, thereby meeting the criteria for a diagnosis of HSP. This case is unique because of the patient's initial presentation with anuria, the possible underlying malignancy associated with his HSP, and his advanced age.
    Cutis; cutaneous medicine for the practitioner 10/2010; 86(4):181-4. · 0.82 Impact Factor
  • Source
    Ravi Ubriani, Marc E Grossman
    [Show abstract] [Hide abstract]
    ABSTRACT: Facial papules (bumps) confront the general practitioner during every face-to-face meeting with the patient. Increased awareness and recognition of the facial papules that represent cutaneous signs of internal malignancy will allow an early, aggressive workup and treatment of any associated cancer. This article details the clinical presentation, etiology, pathologic findings, and associated malignancy for such presentations. A skin biopsy for histopathologic diagnosis is necessary to distinguish these clues to underlying malignancy from the numerous benign lesions that cause facial papules.
    The Medical clinics of North America 11/2009; 93(6):1305-31. · 2.18 Impact Factor
  • [Show abstract] [Hide abstract]
    ABSTRACT: Improvements in imaging technologies have dramatically increased the ability to accurately diagnose and treat many urological disease processes. As urological patients often have chronic kidney disease, the well characterized nephrotoxicity of contrast induced nephropathy when using iodine based contrast materials has long been a concern. With the development of gadolinium based contrast agents it seemed that the concern regarding nephrotoxicity had been resolved. In 1997 a new disorder, nephrogenic systemic fibrosis, appeared in patients with severe renal failure. Nephrogenic systemic fibrosis is a serious and potentially devastating disorder characterized by progressive thickening and hardening of the skin and other body tissues, and complicated by flexion contractures of the joints. We performed a survey of the available literature on nephrogenic systemic fibrosis and magnetic resonance contrast media. We focused on mechanisms in the development of nephrogenic systemic fibrosis as well as its association with magnetic resonance contrast media, disease treatment and prevention, and its relevance to clinical urology. An association between nephrogenic systemic fibrosis and gadolinium based contrast agents has been reported. Gadolinium is a toxic metal and it must be chelated to be a safe injectable contrast agent. It is now hypothesized that the majority of nephrogenic systemic fibrosis cases present with gadolinium based contrast agent exposure as the triggering factor, although this mechanism has not been elucidated. As gadolinium enhanced magnetic resonance imaging is an important tool in the diagnosis and surveillance of urological diseases, the severe consequences of nephrogenic systemic fibrosis demand that practicing urologists understand and know its history and treatment strategies. This review provides clarification of the gadolinium based contrast agent characteristics, tissue interactions that lead to the development of nephrogenic systemic fibrosis, prevention possibilities and available treatment options.
    The Journal of urology 11/2009; 183(1):27-33. · 3.75 Impact Factor
  • [Show abstract] [Hide abstract]
    ABSTRACT: The objective of this article is to review the current knowledge about nephrogenic systemic fibrosis (NSF) and how to prevent it. More than 300 cases of NSF in patients with severe chronic renal insufficiency or acute renal failure or in patients undergoing dialysis have been reported in the peer-reviewed literature, with an overwhelming majority occurring within weeks to months after injection of a gadolinium-based contrast agent (GBCA). Because administration of a high dose of a GBCA is a primary risk factor and because most high-dose magnetic resonance (MR) imaging applications involve abdominal imaging (eg, liver and abdominal MR angiography), NSF cases have been associated with abdominal MR imaging. Additional major risk factors for developing NSF include proinflammatory conditions, failure to perform dialysis promptly after GBCA administration, use of nonionic linear contrast agents, hyperphosphatemia, and younger age. Recent recommendations to use GBCAs with caution in patients with acute renal failure, patients receiving dialysis, or patients with an estimated glomerular filtration rate of less than 30 mL/min have resulted in virtually no new NSF cases being reported with onset in 2008 or 2009 in spite of a high level of awareness about this entity. In conclusion, NSF has been virtually eliminated by using caution in administering GBCAs to patients known to have severe or acute renal failure. In these patients, avoid high doses; and for patients undergoing dialysis, schedule MR imaging to occur just before a dialysis session to ensure rapid elimination of gadolinium.
    Radiographics 10/2009; 29(6):1565-74. · 2.79 Impact Factor

Publication Stats

2k Citations
799.64 Total Impact Points


  • 1981–2014
    • Columbia University
      • • Department of Dermatology
      • • College of Physicians and Surgeons
      • • Division of Nephrology
      New York City, New York, United States
  • 2013
    • University of California, San Diego
      • Department of Medicine
      San Diego, CA, United States
  • 1988–2013
    • New York Presbyterian Hospital
      • Department of Dermatology
      New York City, New York, United States
    • Winthrop University Hospital
      Mineola, New York, United States
  • 2008–2012
    • University of California, San Francisco
      • Department of Dermatology
      San Francisco, CA, United States
    • Kaiser Permanente
      Oakland, California, United States
    • University of Texas Medical School
      Houston, Texas, United States
    • Albert Einstein College of Medicine
      New York City, New York, United States
  • 1997–2012
    • New York University
      • Department of Dermatology
      New York City, NY, United States
  • 2011
    • University of California, Irvine
      Irvine, California, United States
  • 1988–2008
    • CUNY Graduate Center
      New York City, New York, United States
  • 2007
    • State University of New York Downstate Medical Center
      • Department of Dermatology
      Brooklyn, NY, United States
    • Massachusetts General Hospital
      • Department of Dermatology
      Boston, MA, United States
  • 2005–2006
    • Yale-New Haven Hospital
      New Haven, Connecticut, United States
    • Yale University
      New Haven, Connecticut, United States
  • 2004
    • City University of New York - Bronx Community College
      New York City, New York, United States
  • 2003
    • Hadassah Medical Center
      Yerushalayim, Jerusalem District, Israel
  • 2002
    • Saint Luke's Hospital (NY, USA)
      New York City, New York, United States
  • 1993
    • Gracie Square Hospital, New York, NY
      New York City, New York, United States
  • 1979
    • Devry College of New York, USA
      New York City, New York, United States